Ra Pharmaceuticals, which is developing small molecule therapies for rare immune disorders, raised $92 million by offering 7 million shares at $13, within the range of $12 to $14. Ra Pharmaceuticals plans to list on the Nasdaq under the symbol RARX. Credit Suisse, Jefferies and BMO Capital Markets acted as lead managers on the deal.
